7.60
-0.01 (-0.13%)
| Previous Close | 7.61 |
| Open | 7.52 |
| Volume | 676 |
| Avg. Volume (3M) | 22,558 |
| Market Cap | 61,272,416 |
| Price / Sales | 1.87 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| TTM Dividend Yield | 3.29% |
| Profit Margin | -28.04% |
| Operating Margin (TTM) | 17.39% |
| Diluted EPS (TTM) | -1.07 |
| Quarterly Revenue Growth (YOY) | 2.50% |
| Quarterly Earnings Growth (YOY) | 54.50% |
| Current Ratio (MRQ) | 0.610 |
| Operating Cash Flow (TTM) | 7.20 M |
| Levered Free Cash Flow (TTM) | -4.78 M |
| Return on Assets (TTM) | -0.13% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Care Facilities (US) | Mixed | Mixed |
| Medical Care Facilities (Global) | Mixed | Mixed | |
| Stock | Cryo-Cell International, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.0 |
| Average | 0.13 |
|
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida. |
|
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| % Held by Insiders | 47.71% |
| % Held by Institutions | 11.18% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sfi Advisors, Llc | 30 Sep 2024 | 165,300 |
| Massmutual Private Wealth & Trust, Fsb | 31 Dec 2024 | 111,035 |
| Rowlandmiller & Partners.Adv | 30 Sep 2024 | 0 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 30 Oct 2024 | Announcement | Cord Blood Banking Leader Cryo-Cell Declares Initiation of Regular Quarterly Cash Dividend |
| TTM Dividend Yield | 3.29% |
| 3Y Average Dividend Yield | 8.22% |
| Expected Next Dividend Payment | Nov 2025 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 15 Nov 2024 | 30 Oct 2024 | 29 Nov 2024 | 0.25 Cash |
| 01 Sep 2022 | 19 Aug 2022 | 09 Sep 2022 | 0.9 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2024 | 0.250 | 1 | 3.37 |
| 2022 | 0.900 | 1 | 21.28 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |